Full Text View
Tabular View
No Study Results Posted
Related Studies
Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy
This study has been completed.
First Received: July 21, 2008   No Changes Posted
Sponsor: Henry Ford Health System
Information provided by: Henry Ford Health System
ClinicalTrials.gov Identifier: NCT00720980
  Purpose

Granuloma annulare is a benign, usually self-limiting, cutaneous dermatosis, which typically presents as asymptomatic, flesh-colored or red papules, frequently arranged in an annular pattern on the distal extremities. Although localized granuloma annulare is most commonly observed, a generalized or disseminated form can occur. The etiology of granuloma annulare is unknown, however, multiple inciting factors have been proposed. The purpose of the investigators is to review the outcomes of treatment of granuloma annulare (GA) resistant to standard regimens that resolved after a 3-months treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy, successfully used to treat paucibacillary leprosy, a disease with clinical and histopathologic similarity to GA.


Condition
Granuloma Annulare

Study Type: Observational
Study Design: Case-Only, Retrospective
Official Title: Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

Resource links provided by NLM:


Further study details as provided by Henry Ford Health System:

Biospecimen Retention:   None Retained

Biospecimen Description:

Enrollment: 6
Study Start Date: May 2008
Study Completion Date: July 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Detailed Description:

We will document the regimen treatment each patient has had and then review the following from the patient's chart to target our specific aims as outlined above.

  1. What previous treatment options have been or/are currently being used?
  2. How long did the patient take the treatment for?
  3. Was the patient able to discontinue or become less dependent on prior treatment?
  4. Was the disease process slowed by the treatment?;
  5. Were there any side effects that the patient experienced with treatment?
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The investigators reported 6 cases of resistant GA that resolved after a 3-month treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy. ROM therapy has been successfully used to treat patients with paucibacillary leprosy, which has morphologic and histologic similarities to GA.

Criteria

Inclusion Criteria:

  • Patients with granuloma annulare who are resistent to the standard treatment.

Exclusion Criteria:

  • Response to the standard treatment of granuloma annulare.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00720980

Locations
United States, Michigan
Henry Ford Medical Center
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Iltefat H Hamzavi, MD Henry Ford Health System
  More Information

Publications:
Responsible Party: Henry Ford Health System ( Iltefat H. Hamzavi, MD )
Study ID Numbers: IRB5074
Study First Received: July 21, 2008
Last Updated: July 21, 2008
ClinicalTrials.gov Identifier: NCT00720980     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Henry Ford Health System:
granuloma annulare, ROM

Additional relevant MeSH terms:
Anti-Infective Agents
Minocycline
Molecular Mechanisms of Pharmacological Action
Collagen Diseases
Skin Diseases
Ofloxacin
Anti-Infective Agents, Urinary
Enzyme Inhibitors
Renal Agents
Granuloma
Pharmacologic Actions
Lymphatic Diseases
Anti-Bacterial Agents
Pathologic Processes
Therapeutic Uses
Necrobiotic Disorders
Connective Tissue Diseases
Lymphoproliferative Disorders
Nucleic Acid Synthesis Inhibitors
Granuloma Annulare

ClinicalTrials.gov processed this record on February 08, 2010